GENE-THERAPEUTIC DNA VECTOR BASED ON THE GENE-THERAPEUTIC DNA VECTOR VTvaf17, CARRYING THE TARGET GENE SELECTED FROM THE GROUP OF SKI, TGFB3, TIMP2, FMOD GENES TO INCREASE THE LEVEL OF EXPRESSION OF THESE TARGET GENES, A METHOD FOR PREPARING AND USING IT, ESCHERICHIA COLI SCS110-AF/VTvaf17-SKI STRAIN OR ESCHERICHIA COLI SCS110-AF/VTvaf17-TGFB3 OR ESCHERICHIA COLI SCS110-AF/VTvaf17-TIMP2 OR ESCHERICHIA COLI SCS110-AF/VTvaf17-FMOD, CARRYING A GENE-THERAPEUTIC DNA VECTOR, A METHOD FOR PRODUCTION THEREOF, A METHOD FOR INDUSTRIAL PRODUCTION OF A GENE-THERAPEUTIC DNA VECTOR
FIELD: biochemistry.SUBSTANCE: invention relates to genetic engineering. Described is a gene-therapeutic DNA vector based on the gene-therapeutic DNA vector VTvaf17 for treating diseases characterized by developing tissue fibrosis, scar formation, connective tissue damage and accelerated wound healing, re-epithelialization, to increase formation of granulation tissue and inhibition of scar tissue formation, by increasing expression level of target SKI gene in human body and animals, wherein the gene-therapeutic DNA vector contains a coding portion of the target SKI gene cloned into the VTvaf17 genotyping DNA vector to obtain a VTvaf17-SKI gene-therapeutic DNA vector, with the nucleotide sequence SEQ ID No. 1. What is also described is a gene-therapeutic DNA vector based on the VTvaf17 gene-therapeutic DNA vector for treating diseases characterized by developing tissue fibrosis, scar formation, connective tissue damage and accelerated wound healing, re-epithelialization, to increase formation of granulation tissue and inhibition of scar tissue formation, by increasing expression level of target gene TGFB3, wherein the gene-therapeutic DNA vector comprises a coding portion of the target TGFB3 gene cloned into the VTvaf17 gene-therapeutic DNA vector to obtain a VTvaf17-TGFB3 gene-therapeutic DNA vector with the nucleotide sequence SEQ ID No. 2. What is also described is a gene-therapeutic DNA vector based on the gene-therapeutic DNA vector VTvaf17 for treating diseases characterized by developing tissue fibrosis, scar formation, connective tissue damage and accelerated wound repair, re-epithelialization, to increase the formation of granulation tissue and to inhibit the formation of scar tissue, by increasing the expression level of the target TIMP2 gene, wherein the gene-therapeutic DNA vector contains a coding portion of the target TIMP2 gene cloned into the VTvaf17 gene-genetic DNA vector, to obtain a VTvaf17-TIMP2 gene-therapeutic DNA vector, with the nucleotide se
